Moomoo AI 已提取核心信息
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced on February 1, 2024, an exclusive long-term licensing agreement with BIRAD, the research and development arm of Bar-Ilan University in Israel. This agreement grants Clearmind the rights to use a joint patent with BIRAD for an innovative treatment for cocaine addiction. The treatment is based on the compound MEAI [5-Methoxy-2-aminoindane], which has shown promising results in pre-clinical trials by significantly reducing cocaine craving and addiction. The trials, led by Professor Gal Yadid at the Gonda Multidisciplinary Brain Research Center, utilized the self-administration paradigm to demonstrate MEAI's potential in treating cocaine addiction without being addictive itself. Clearmind's CEO, Dr. Adi Zuloff-Shani, expressed that securing the exclusive rights aligns with the company's strategic decision to ensure maximum returns for shareholders and to provide innovative treatments for addiction. The company's shares are traded on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange under the symbols 'CMND' and 'CWY' respectively.
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced on February 1, 2024, an exclusive long-term licensing agreement with BIRAD, the research and development arm of Bar-Ilan University in Israel. This agreement grants Clearmind the rights to use a joint patent with BIRAD for an innovative treatment for cocaine addiction. The treatment is based on the compound MEAI [5-Methoxy-2-aminoindane], which has shown promising results in pre-clinical trials by significantly reducing cocaine craving and addiction. The trials, led by Professor Gal Yadid at the Gonda Multidisciplinary Brain Research Center, utilized the self-administration paradigm to demonstrate MEAI's potential in treating cocaine addiction without being addictive itself. Clearmind's CEO, Dr. Adi Zuloff-Shani, expressed that securing the exclusive rights aligns with the company's strategic decision to ensure maximum returns for shareholders and to provide innovative treatments for addiction. The company's shares are traded on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange under the symbols 'CMND' and 'CWY' respectively.
专门从事迷幻药物衍生疗法的生物技术公司Clearmind Medicine Inc. 于2024年2月1日宣布与以色列巴伊兰大学的研发部门BIRAD签订独家长期许可协议。该协议授予Clearmind使用与BIRAD的联合专利来治疗可卡因成瘾的创新疗法的权利。该疗法基于化合物MEAI [5-甲氧基-2-氨基吲哚烷]，该化合物通过显著减少对可卡因的渴望和成瘾，在临床前试验中显示出令人鼓舞的结果。这些试验由贡达多学科大脑研究中心的加尔·亚迪德教授领导，利用自我管理模式来证明MEAI在不成瘾的情况下治疗可卡因成瘾的潜力。Clearmind首席执行官阿迪·祖洛夫-沙尼博士表示，获得专有权利符合公司的战略决策，以确保股东获得最大回报，并为成瘾提供创新的治疗方法。该公司的股票在纳斯达克、加拿大证券交易所和法兰克福证券交易所上市，股票代码分别为 “CMND” 和 “CWY”。
专门从事迷幻药物衍生疗法的生物技术公司Clearmind Medicine Inc. 于2024年2月1日宣布与以色列巴伊兰大学的研发部门BIRAD签订独家长期许可协议。该协议授予Clearmind使用与BIRAD的联合专利来治疗可卡因成瘾的创新疗法的权利。该疗法基于化合物MEAI [5-甲氧基-2-氨基吲哚烷]，该化合物通过显著减少对可卡因的渴望和成瘾，在临床前试验中显示出令人鼓舞的结果。这些试验由贡达多学科大脑研究中心的加尔·亚迪德教授领导，利用自我管理模式来证明MEAI在不成瘾的情况下治疗可卡因成瘾的潜力。Clearmind首席执行官阿迪·祖洛夫-沙尼博士表示，获得专有权利符合公司的战略决策，以确保股东获得最大回报，并为成瘾提供创新的治疗方法。该公司的股票在纳斯达克、加拿大证券交易所和法兰克福证券交易所上市，股票代码分别为 “CMND” 和 “CWY”。
有用
没用